ReCell Placement and Medical Procedure Overview

Investment highlights Frontier of medical technology Unique product offering Potential of the technology is recognised by US DoD Established track record Regenerative medicine in wound care is one of fastest growing areas in healthcare and offers vast potential for unmet therapeutic needs ReCell® services a significant market for the treatment of burns, reconstructive/plastic applications, vitiligio and aesthetics; estimated at approximately 2-3 million treatments p.a. ReCell® Spray-on-Skin is rapid, low cost, minimises scarring, has a low risk of infection, minimises the donor site (stamp-size vs. up to 30cm x 30cm), has no lab requirements and can be used in combination with other techniques There is no similar harvesting, processing and delivery device for autologous tissue commercially available The US Department of Defense has provided a cash grant, contract and clinical trial support for the ReCell® technology; this enhances ReCell® credibility and recognition of the technology's potential Avita's burns study is the only study conducted by a non-US company to receive such support from the US Armed Forces (as part of the AFIRM trial) Over 3,500 patients have been treated with ReCell® Spray-on-Skin ReCell's® Spray-on-Skin has been embraced by key influential surgeons and Centres of Excellence in the UK, France and Germany Avita has an experienced management team Philanthropic acknowledgement ReCell® Spray-on-Skin was used to help the Bali bomb victims Inventor and Director, Professor Fiona Woods, was awarded Australian of the Year in 2005 34 medical avita

View entire presentation